Beyond Glycaemia: Fear of Hypoglycaemia, Cognition and Functional Mobility After Advanced Hybrid Closed‐Loop Therapy in Older Adults With Type 1 Diabetes: A Prespecified Secondary Analysis of a Randomised, Single‐Centre Study

Diabetes Obes MetabPublished Prespecified secondary analysis of a randomised controlled trial

Authors' conclusion

In this small, selected cohort, AHCL therapy was associated with a nominally lower fear-of-hypoglycaemia score and better performance on selected mobility-related tests over 12 months. The fear-of-hypoglycaemia finding did not remain statistically significant after correction for multiple comparisons or additional adjustment for sex. Six-minute walk distance and Timed Up and Go remained statistically significant in the exploratory sex-adjusted sensitivity analyses, whereas the gait-speed difference did not. No measurable between-group deterioration in global cognition or processing speed was observed.

Study context

Population
Adults aged ≥ 65 years with long-standing T1D29 completed
Participants
31 adults
Comparison
Advanced hybrid closed-loop (AHCL) therapy vs standard diabetes treatment
Primary endpoint
HFS-II score (baseline-adjusted primary analysis)
Follow-up
12 months
Methodological detailsexploratory, single-centre, open-label, parallel-group, No formal sample-size calculation for these secondary outcomes
  • Exploratory
  • Single-centre
  • Open-label
  • Parallel-group
  • No formal sample-size calculation for these secondary outcomes

Primary result

As reported in the abstract

HFS-II score
AHCL vs Standard treatmentEstimate (95% CI)P value
Holm correction: adjusted p = 0.104
adjusted mean difference −18.9(−32.4 to −5.4)
nominal p = 0.008
Exploratory model additionally adjusted for sex
difference −13.6(−32.2 to 5.0)
P = 0.145

Secondary outcomes

HFS-II score, exploratory model additionally adjusted for sex · 12 months

Exploratory

6-min walk distance, sex-adjusted sensitivity analysis · 12 months

Between-group difference in 6-min walk distance remained statistically significant
92.6 m (95% CI: 36.8 to 148.3; p = 0.002)
  • Sex-adjusted sensitivity analysis

Timed Up and Go performance, sex-adjusted sensitivity analysis · 12 months

Between-group difference in Timed Up and Go remained statistically significant
−2.27 s (95% CI: −4.28 to −0.27; p = 0.028)
  • Sex-adjusted sensitivity analysis

Gait speed, sex-adjusted sensitivity analysis · 12 months

Between-group difference in gait speed not statistically significant
0.27 m/s (95% CI: −0.05 to 0.59; p = 0.099)
  • Sex-adjusted sensitivity analysis

Diabetes distress, psychological well-being, global cognition and processing speed · 12 months

Did not differ between groups

Fried frailty phenotype · 12 months

AHCL: robust
12 of 14
AHCL: pre-frail
2
Control: robust
11 of 15
Control: pre-frail
4
Frail at follow-up
0

Original publication

Beyond Glycaemia: Fear of Hypoglycaemia, Cognition and Functional Mobility After Advanced Hybrid Closed‐Loop Therapy in Older Adults With Type 1 Diabetes: A Prespecified Secondary Analysis of a Randomised, Single‐Centre Study. Diabetes Obes Metab. Published 30 July 2026. doi:10.1111/dom.71170

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.